



MEET DANNY

A patient who is trigger avoidant
with a low attack history*

THE INTERNATIONAL WAO/EAACI GUIDELINES STATE:

- High HAE disease activity often comes with impact on daily life. The daily lives of some patients with low attack rates are also impacted, thought to be linked to the unpredictability and continuous fear of HAE attacks¹
- Since most attacks are unpredictable and not prompted by triggers, guidelines suggest that physicians should not support excessive avoidance of triggers as this can limit a patient's normal life¹

*Danny is a hypothetical patient with HAE.

EAACI=European Academy of Allergy and Clinical Immunology; WAO=World Allergy Organization.

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥ 2 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Please see additional Important Safety Information throughout and full [Prescribing Information](#).


TAKHZYRO[®]
(lanadelumab-flyo) injection

MEET DANNY

Attitudes

- Reports minimal disease impact, yet fears his next attack
- Organizes his life around avoiding perceived triggers
- Does not want to think about his HAE every day
- Makes decisions based on demonstrated outcomes and the experiences of other patients with HAE

Treatment

- Currently uses acute therapy only*

Unpredictability of HAE

- Has not noticed an increase in his HAE attacks in recent years, but frequently recalls getting several unexpected attacks triggered by a stressful work project

Minimizing attacks

- Downplays attacks in his extremities as "swells" and has not yet considered how long-term prevention could help manage his HAE

As an on-the-go parent, Danny looks forward to family activities, such as bike rides. **However, he sometimes chooses to skip them to avoid vibrations that might trigger a hand swell.**

*TAKHZYRO is a preventive therapy. Please see the full indication.

IMPORTANT SAFETY INFORMATION (cont'd)


Adverse Reactions: The most commonly observed adverse reactions ($\geq 10\%$) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; dizziness; diarrhea; and myalgia. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Does Danny remind you of one of your patients with HAE?

- Do they experience swells in their extremities, but do not classify them as attacks?
- Do they avoid activities because of their HAE?
- Would they live their life differently if they were on a preventive treatment?

Please see additional Important Safety Information throughout and full [Prescribing Information](#).


TAKHZYRO[®]
(lanadelumab-flyo) injection



WHAT COULD THE **TAKHZYRO EXPERIENCE** MEAN FOR YOUR PATIENTS?

Talk to your Takeda representative to learn how TAKHZYRO could be right for patients like Danny

Unsure who to contact? [Connect with a rep.](#)

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥ 2 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions ($\geq 10\%$) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; dizziness; diarrhea; and myalgia. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients < 2 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-877-TAKEDA-7 (1-877-825-3327), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full [Prescribing Information](#).

Reference: 1. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2021 revision and update. *Allergy*. 2022;77(7):1961-1990. doi:10.1111/all.15214



©2023 Takeda Pharmaceuticals U.S.A., Inc., 300 Shire Way, Lexington, MA 02421. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA® and the TAKEDA Logo® are registered trademarks of Takeda Pharmaceutical Company Limited. TAKHZYRO® is a registered trademark of Dyax Corp. US-LANA-1973v1.0 09/23

TAKHZYRO®
(lanadelumab-flyo) injection